TY  - CHAP
M1  - Book, Section
TI  - DNA Disruptors: Sulfonamides, Quinolones, and Nitroimidazoles
A1  - MacDougall, Conan
A2  - Brunton, Laurence L.
A2  - Knollmann, Björn C.
PY  - 2023
T2  - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition
AB  - Content  UpdateFebruary  6,  2025A  Promising  and  Novel  Agent  for  Treating  Fluroquinolones-resistant  Gonorrhea:  Spiropyrimidinetriones  (zoliflodacin):  Spiropyrimidinetriones  are  a  novel  antimicrobial  class  in  development  that  targets  bacterial  topoisomerases  with  mechanisms  similar  to  but  distinct  from  that  of  fluoroquinolones.  The  most  advanced  agent  in  the  class,  zoliflodacin,  has  shown  potential  as  a  first-line  therapy  for  gonorrhea,  especially  in  areas  where  resistance  to  standard  therapies  is  high.  The  development  of  zoliflodacin  is  the  result  of  a  partnership  between  a  nonprofit  group  (Global  Antibiotic  Research  and  Development  Partnership,  GARDP)  and  a  commercial  pharmaceutical  company.Zoliflodacin  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2025/07/15
UR  - hemonc.mhmedical.com/content.aspx?aid=1212623534
ER  -